Pfizer Will Likely Overpay For M&A Post-Allergan Breakup Flop: Jeffries
Pfizer was downgraded by an analyst who sees a lack of near-term catalysts. (iStockphoto) No. 2...
WHAT'S UP IN
Mergers and acquisitions
Pfizer’s Growth Strategies May Need More Than Just Small Acquisitions
Summary After its failed attempts for a merger with Allergan and AstraZeneca to bolster its drug...
